With box warnings

Without box warnings

Branded

Generic

3 results

ixempra
(ixabepilone)
R-Pharm US Operating, LLC
Usage: IXEMPRA is indicated for treating patients with metastatic or locally advanced breast cancer that is resistant to anthracyclines and taxanes, or when further anthracycline therapy is contraindicated. It can be used in combination with capecitabine or as a single agent when tumors are resistant to multiple treatments.
letrozole
(Letrozole Tablets)
Yiling Pharmaceutical, Inc.
Usage: Letrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for extended adjuvant therapy following tamoxifen. It is also used as a first and second-line treatment for advanced, locally advanced, or metastatic breast cancer in postmenopausal women.
tykerb
(lapatinib)
Novartis Pharmaceuticals Corporation
Usage: TYKERB® is indicated for advanced or metastatic breast cancer in combination with capecitabine for HER2-overexpressing tumors after prior therapies, and with letrozole for postmenopausal women with hormone receptor-positive, HER2-overexpressing metastatic breast cancer where hormonal therapy is appropriate. Prior progression on trastuzumab is required.

Medications for Locally Advanced Breast Cancer

ixempra